⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DARE News
Dare Bioscience, Inc. Common Stock
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026
globenewswire.com
DARE
Form 8-K
sec.gov
DARE
Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules
globenewswire.com
DARE
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
globenewswire.com
DARE
Form 8-K
sec.gov
DARE
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
globenewswire.com
DARE
Form 8-K
sec.gov
DARE
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
DARE
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
globenewswire.com
DARE
Form 8-K
sec.gov
DARE